MUFG Americas’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

MUFG Americas’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-420	Closed	-$5K	–	1207
2016 Q2	$5K	Buy	420 +250	+147%	+$3.03K	﹤0.01%	1035
2016 Q1	$2K	Buy	+170	New	+$2K	﹤0.01%	1134
2015 Q4	–	Sell	-150	Closed	-$2K	–	1321
2015 Q3	$2K	Buy	+150	New	+$3.01K	﹤0.01%	1136

Other funds holding OMED

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MUFG Americas's OMED Position: Q3 2016 in Review

MUFG Americas sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q3 2016, closing a stake of 420 shares — an estimated $5K sold.

MUFG Americas first reported a position in OMED in Q3 2015 and held it in 3 quarters. The position peaked at $5K in Q2 2016. 89 funds tracked by Wall St. Rank hold OMED as of Q3 2016.

MUFG Americas reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
MUFG Americas sold 420 OncoMed Pharmaceuticals, Inc. shares in Q3 2016, an estimated $5K.
MUFG Americas first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2015 and held it in 3 quarters.
MUFG Americas's OncoMed Pharmaceuticals, Inc. position peaked at $5K in Q2 2016.
89 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q3 2016.

Based on MUFG Americas's 13F filing for Q3 2016, filed 14 Nov 2016.